RxDoctor Payments Data

Brandon Cottrell, MD

Urology · Oak Ridge, TNNPI 1679694640

Payments from drug & device makers

$5,604in general payments, 2019–2025

Across 148 payments — averaging $37.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$1K
  • Teleflex LLC$513
  • Sumitomo Pharma America, Inc.$484
  • Astellas Pharma US Inc$364
  • Neotract Inc.$185
  • plus $824 from 17 others

What the payments were for

  • Speaking & faculty fees$1172%
  • Travel & lodging$80214%
  • Food & beverage$4,54581%
  • Education$1413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,604 in reported general payments places this provider in the 60th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$66,513
Medicare patients
306
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron259$172,090
GemtesaVibegron239$140,839
Solifenacin Succinate576$16,999
Testosterone63$10,146
Tamsulosin Hcl967$9,347
Methenamine Hippurate101$7,440
Dutasteride248$7,011
Finasteride381$5,391
Testosterone Cypionate122$4,422
Cefdinir212$3,292
Tolterodine Tartrate ErTolterodine Tartrate54$3,275
Potassium Citrate ErPotassium Citrate44$3,233
Fesoterodine Fumarate ErFesoterodine Fumarate22$1,996
Estradiol22$1,421
Bethanechol Chloride17$1,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$364$172,090259 claims
Sumitomo Pharma America, Inc.Gemtesa$484$140,839239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 276 urology providers in Tennessee.

Other urology in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →